S061 The 2024 Debates: Controversies in Dermatology
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Evidence-based medicine is the conscientious and judicious use of the strongest current data in making decisions on how we care for our patients. Advances in technology, development of new therapies, and acquisition of new data challenge our best practices and may at the same time stimulate controversy. This session is designed for interactive discussion and critical thinking regarding some of the emerging issues that we are actively encountering in 2024.
LEARNING OBJECTIVES
Critically evaluate key issues and challenges in deploying molecular testing for the determination of melanoma risk and outcomes.
Define and recognize the current opportunities and challenges with developing and using Artificial Intelligence applications in dermatology.
Critically evaluate the key issues and challenges associated with melanoma (over)diagnosis and skin cancer screening.
SCHEDULE
8:00 PM
Introduction
Kenneth Y. Tsai, MD, PhD, FAAD
8:05 PM
Applications of Artificial Intelligence in Dermatology - Part 1
Yevgeniy Semenov, MD, MS, FAAD
8:25 PM
Applications of Artificial Intelligence in Dermatology - Part 2
Shannon Wongvibulsin, MD, PhD
8:45 PM
Open Discussion
Yevgeniy Semenov, MD, MS, FAAD, Shannon Wongvibulsin, MD, PhD
9:05 PM
The Clinical Utility of Molecular Testing in Melanoma - Part 1
Pedram Gerami, MD
9:25 PM
The Clinical Utility of Molecular Testing in Melanoma - Part 2
Emily Y. Chu, MD, PhD, FAAD
9:45 PM
Open Discussion
Emily Y. Chu, MD, PhD, FAAD, Pedram Gerami, MD
10:05 PM
The Challenges of Melanoma (Over)Diagnosis and Screening - Part 1
David Polsky, MD, PhD, FAAD
10:25 PM
The Challenges of Melanoma (Over)Diagnosis and Screening - Part 2
Allan C. Halpern, MD, FAAD
10:45 PM
Open Discussion
Allan C. Halpern, MD, FAAD, David Polsky, MD, PhD, FAAD
SPEAKERS
Emily Y. Chu, MD, PhD, FAAD
Pedram Gerami, MD
Allan C. Halpern, MD, FAAD
David Polsky, MD, PhD, FAAD
Yevgeniy Semenov, MD, MS, FAAD
Kenneth Y. Tsai, MD, PhD, FAAD
Hensin Tsao, MD, PhD, FAAD
Shannon Wongvibulsin, MD, PhD
SPEAKER DISCLOSURES
Emily Y. Chu, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Pedram Gerami, MD
Castle Biosciences, Inc – Consultant(Honoraria); DermTech International – Consultant(Honoraria);
Allan C. Halpern, MD, FAAD
Canfield Scientific, Inc. – Consultant(Other Financial Benefit); SciBASE – Consultant(Other Financial Benefit); SpotDoc – Founder(Other Financial Benefit);
David Polsky, MD, PhD, FAAD
BMS – Independent Contractor(Grants/Research Funding); Medscape – Speaker(Honoraria); MoleSafe, Inc. – Other(Fees); Novartis – Independent Contractor(Grants/Research Funding); Viela Bio – Advisory Board(Stock);
Yevgeniy Semenov, MD, MS, FAAD
Castle Biosciences, Inc – Advisory Board(Honoraria); Galderma USA – Consultant(Honoraria); Incyte Corporation – Consultant(Honoraria); Journal of the American Academy of Dermatology – Other(Salary); Pfizer Inc. – Consultant (1099 relationship)(Honoraria); Sanofi/Regeneron – Consultant(Honoraria);
Kenneth Y. Tsai, MD, PhD, FAAD
3CC - Third Culture Capital – Stockholder(No Compensation Received); Altos Labs – Consultant (1099 relationship)(Fees); APIS Assay Technologies – Independent Contractor(Grants/Research Funding); DX Biosciences, Inc – Consultant(Stock Options); Incyte Corporation – Investigator(Grants/Research Funding); NFlection Therapeutics, Inc – Consultant(Fees); UpToDate – Independent Contractor(Fees); Verrica Pharmaceuticals Inc – Independent Contractor(Fees);
Hensin Tsao, MD, PhD, FAAD
Epiphany Dermatology – Advisory Board(Honoraria), Advisory Board(Stock Options); Massachusetts General Hospital – Employee(Salary); Oncobay Clinical – Consultant (1099 relationship)(Fees); UpToDate, Inc. – Other(Honoraria); Worldcare Clinical, LLC – Consultant (1099 relationship)(Fees);
Shannon Wongvibulsin, MD, PhD
No financial relationships exist with ineligible companies.